Equities

OXB

OXB:LSE

OXB

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)809.00
  • Today's Change-3.00 / -0.37%
  • Shares traded158.96k
  • 1 Year change99.75%
  • Beta3.0186
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year OXB grew revenues 43.84% from 89.54m to 128.80m while net income improved from a loss of 157.49m to a smaller loss of 43.19m.
Gross margin44.12%
Net profit margin-25.85%
Operating margin-20.31%
Return on assets-16.95%
Return on equity-74.89%
Return on investment-23.87%
More ▼

Cash flow in GBPView more

In 2024, cash reserves at OXB fell by 43.07m. However, Cash Flow from Investing totalled 5.63m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 50.67m for operations while cash generated from financing totalled 2.91m.
Cash flow per share-0.1441
Price/Cash flow per share--
Book value per share0.3084
Tangible book value per share0.0793
More ▼

Balance sheet in GBPView more

OXB has a Debt to Total Capital ratio of 76.31%, a lower figure than the previous year's 159.21%.
Current ratio1.89
Quick ratio1.67
Total debt/total equity3.22
Total debt/total capital0.7631
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.